Skip to main content

Table 5 Adverse events occurring in at least 5% of patients in either treatment group

From: An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

  pAT (N = 113) AT gamma (N = 108)
Number of patients (%) Number of events Number of patients (%) Number of events
Erythema 12 (10.6) 14 18 (16.7) 19
Diarrhea 6 (5.3) 6 17 (15.7) 18
Decubitus ulcer 10 (8.8) 12 12 (11.1) 13
Pneumonia 6 (5.3) 6 10 (9.3) 10
Vomiting 7 (6.2) 8 9 (8.3) 11
Constipation 4 (3.5) 5 9 (8.3) 9
Insomnia 10 (8.8) 10 9 (8.3) 9
Anemia 8 (7.1) 9 7 (6.5) 7
Sepsis 8 (7.1) 8 6 (5.6) 6
Hypokalemia 9 (8.0) 9 5 (4.6) 7
Hypernatremia 6 (5.3) 6 4 (3.7) 4
Pleural effusion 8 (7.1) 8 4 (3.7) 4
Nausea 7 (6.2) 7 3 (2.8) 4
Hepatic function abnormal 6 (5.3) 6 3 (2.8) 3
Blood bilirubin increased 6 (5.3) 6 3 (2.8) 3
Delirium 6 (5.3) 6 3 (2.8) 3
Skin exfoliation 11 (9.7) 17 3 (2.8) 3
  1. pAT plasma-derived antithrombin